Latest California Healthline Stories
A Father Dreamed of a Home for His Family. Medical Debt Nearly Pushed Them Onto the Streets.
As cities like Denver struggle to make homes more affordable, medical debt keeps housing out of reach for millions of Americans.
Pfizer, Moderna Push the New Covid Booster. Should You Get It? The CDC Is About to Decide.
Chances are, if you aren’t older, chronically ill, or obese, you don’t need a forthcoming covid vaccine to stay out of the hospital. But it probably wouldn’t hurt.
Un padre soñaba con una casa para su familia. La deuda médica casi los deja en la calle
En todo el país, la deuda médica obliga a legiones de estadounidenses a hacer sacrificios dolorosos. Muchos recortan gastos en alimentos, asumen trabajos adicionales o agotan sus ahorros para la jubilación. Miles no pueden conseguir vivienda.
A pesar de las amplias recomendaciones para el refuerzo anticovid actualizado publicadas el otoño pasado, sólo el 17% de la población la recibió, y alrededor del 43% de las personas de 65 años o más.
5 Things to Know About the New Drug Pricing Negotiations
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
She Paid Her Husband’s Hospital Bill. A Year After His Death, They Wanted More Money.
A widow encountered a perplexing reality in medical billing: Providers can come after patients to collect well after a bill has been paid.
Timing and Cost of New Vaccines Vary by Virus and Health Insurance Status
Flu. Covid. RSV. When and how to get vaccinated against them can be confusing. Here are some of the most important things to know.
After Backlash, Feds Cancel Plan That Risked Limiting Breast Reconstruction Options
The Centers for Medicare & Medicaid Services backed off from a plan that could have curtailed access to a type of reconstructive surgery known as DIEP flap. Breast cancer patient advocates are relieved.
A Peek at Big Pharma’s Playbook That Leaves Many Americans Unable to Afford Their Drugs
Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?
Sin barreras, los precios de algunos medicamentos existentes se han disparado, incluso cuando han caído drásticamente en otros países. Los nuevos medicamentos tienen precios enormes, respaldados por el lobby y el marketing.